All newsletters
Oct 19, 2023

Time Sensitive Message from Dr. Rand and Team

Share This Newsletter

In this newsletter

FDA Update

Recently, the FDA issued a statement that prohibits the compounding of certain peptides and peptidomimetics (Ibutamoren, CJC-1295/Ipamorelin, and BPC-157 to name a few). Many peptides and peptidomimetics will no longer be available.

Some pharmacies are continuing to process requests for these peptides and peptidomimetics through October 20, 2023. To request these substances before 4p PST on this date, please call 310-452-3206, respond to this email, or access your patient portal and send a message to “Prescription Refills.”

Best in Health,

Michael Bell

Chief Operating Officer

Start your journey to personalized, long-term health

  • Ongoing support focused on long-term health
  • Advanced testing and clear next steps
  • Ongoing support focused on long-term health